To Evaluate the Safety and Effectiveness of Atorvastatin Plus a Cholinesterase Inhibitor in AD Patients.

NCT ID: NCT00151502

Last Updated: 2021-02-18

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

600 participants

Study Classification

INTERVENTIONAL

Study Start Date

2002-11-30

Study Completion Date

2007-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to find out if atovastatin, when taken with a cholinesterase inhibitor, is effective for treating Alzheimer's disease.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Alzheimer's Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Atorvastatin

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Diagnostic evidence of probable Alzheimer's disease consistent with NINCDS/ADRDA and DSM IV criteria.
* Subject's Mini-Mental Status Examination Score (MMSE) must be in the range of 13 - 25 (inclusive) at Screening.

Exclusion Criteria

* Subjects with dementia due to causes other than Alzheimer's disease.
* Any condition, which, in the investigator's judgment might increase the risk to the subject or decrease the reliability of the data required to meet the objectives of the study.
Minimum Eligible Age

50 Years

Maximum Eligible Age

90 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Pfizer CT.gov Call Center

Role: STUDY_DIRECTOR

Pfizer

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Pfizer Investigational Site

Sun City, Arizona, United States

Site Status

Pfizer Investigational Site

Fresno, California, United States

Site Status

Pfizer Investigational Site

Laguna Hills, California, United States

Site Status

Pfizer Investigational Site

San Francisco, California, United States

Site Status

Pfizer Investigational Site

Fort Lauderdale, Florida, United States

Site Status

Pfizer Investigational Site

Fort Myers, Florida, United States

Site Status

Pfizer Investigational Site

Miami Beach, Florida, United States

Site Status

Pfizer Investigational Site

Pompano Beach, Florida, United States

Site Status

Pfizer Investigational Site

St. Petersburg, Florida, United States

Site Status

Pfizer Investigational Site

West Palm Beach, Florida, United States

Site Status

Pfizer Investigational Site

Fort Wayne, Indiana, United States

Site Status

Pfizer Investigational Site

Paducah, Kentucky, United States

Site Status

Pfizer Investigational Site

New Orleans, Louisiana, United States

Site Status

Pfizer Investigational Site

South Dartmouth, Massachusetts, United States

Site Status

Pfizer Investigational Site

West Yarmouth, Massachusetts, United States

Site Status

Pfizer Investigational Site

Worcester, Massachusetts, United States

Site Status

Pfizer Investigational Site

Kalamazoo, Michigan, United States

Site Status

Pfizer Investigational Site

Jamesburg, New Jersey, United States

Site Status

Pfizer Investigational Site

Princeton, New Jersey, United States

Site Status

Pfizer Investigational Site

Albuquerque, New Mexico, United States

Site Status

Pfizer Investigational Site

Albany, New York, United States

Site Status

Pfizer Investigational Site

Rochester, New York, United States

Site Status

Pfizer Investigational Site

Troy, New York, United States

Site Status

Pfizer Investigational Site

Tulsa, Oklahoma, United States

Site Status

Pfizer Investigational Site

Allentown, Pennsylvania, United States

Site Status

Pfizer Investigational Site

Allentown, Pennsylvania, United States

Site Status

Pfizer Investigational Site

Jenkintown, Pennsylvania, United States

Site Status

Pfizer Investigational Site

Pittsburgh, Pennsylvania, United States

Site Status

Pfizer Investigational Site

Pittsburgh, Pennsylvania, United States

Site Status

Pfizer Investigational Site

East Providence, Rhode Island, United States

Site Status

Pfizer Investigational Site

Providence, Rhode Island, United States

Site Status

Pfizer Investigational Site

Madison, Tennessee, United States

Site Status

Pfizer Investigational Site

Austin, Texas, United States

Site Status

Pfizer Investigational Site

Dallas, Texas, United States

Site Status

Pfizer Investigational Site

Houston, Texas, United States

Site Status

Pfizer Investigational Site

Wichita Falls, Texas, United States

Site Status

Pfizer Investigational Site

Richmond, Virginia, United States

Site Status

Pfizer Investigational Site

Seattle, Washington, United States

Site Status

Pfizer Investigational Site

Madison, Wisconsin, United States

Site Status

Pfizer Investigational Site

Milwaukee, Wisconsin, United States

Site Status

Pfizer Investigational Site

East Gosford, New South Wales, Australia

Site Status

Pfizer Investigational Site

Randwick, New South Wales, Australia

Site Status

Pfizer Investigational Site

Daw Park, South Australia, Australia

Site Status

Pfizer Investigational Site

Woodville South, South Australia, Australia

Site Status

Pfizer Investigational Site

Ballarat, Victoria, Australia

Site Status

Pfizer Investigational Site

WEST Heidelberg, Victoria, Australia

Site Status

Pfizer Investigational Site

Nedlands, Western Australia, Australia

Site Status

Pfizer Investigational Site

Vienna, , Austria

Site Status

Pfizer Investigational Site

Vienna, , Austria

Site Status

Pfizer Investigational Site

Wein, , Austria

Site Status

Pfizer Investigational Site

Calgary, Alberta, Canada

Site Status

Pfizer Investigational Site

Vancouver, British Columbia, Canada

Site Status

Pfizer Investigational Site

Halifax, Nova Scotia, Canada

Site Status

Pfizer Investigational Site

London, Ontario, Canada

Site Status

Pfizer Investigational Site

Toronto, Ontario, Canada

Site Status

Pfizer Investigational Site

Montreal, Quebec, Canada

Site Status

Pfizer Investigational Site

Montreal, Quebec, Canada

Site Status

Pfizer Investigational Site

Québec, Quebec, Canada

Site Status

Pfizer Investigational Site

Verdun, Quebec, Canada

Site Status

Pfizer Investigational Site

Aarhus, , Denmark

Site Status

Pfizer Investigational Site

Copenhagen, , Denmark

Site Status

Pfizer Investigational Site

Hillerød, , Denmark

Site Status

Pfizer Investigational Site

Rudkøbing, , Denmark

Site Status

Pfizer Investigational Site

Svendborg, , Denmark

Site Status

Pfizer Investigational Site

Bad Honnef, , Germany

Site Status

Pfizer Investigational Site

Berlin, , Germany

Site Status

Pfizer Investigational Site

Bochum, , Germany

Site Status

Pfizer Investigational Site

Bonn, , Germany

Site Status

Pfizer Investigational Site

Göttingen, , Germany

Site Status

Pfizer Investigational Site

Hanover, , Germany

Site Status

Pfizer Investigational Site

München, , Germany

Site Status

Pfizer Investigational Site

München, , Germany

Site Status

Pfizer Investigational Site

Tübingen, , Germany

Site Status

Pfizer Investigational Site

Rosebank, Gauteng, South Africa

Site Status

Pfizer Investigational Site

Willows, Gauteng, South Africa

Site Status

Pfizer Investigational Site

Pinetown, KwaZulu-Natal, South Africa

Site Status

Pfizer Investigational Site

Belleville, , South Africa

Site Status

Pfizer Investigational Site

Westville, , South Africa

Site Status

Pfizer Investigational Site

Terrassa, Barcelona, Spain

Site Status

Pfizer Investigational Site

Barcelona, , Spain

Site Status

Pfizer Investigational Site

Barcelona, , Spain

Site Status

Pfizer Investigational Site

Barcelona, , Spain

Site Status

Pfizer Investigational Site

Madrid, , Spain

Site Status

Pfizer Investigational Site

Madrid, , Spain

Site Status

Pfizer Investigational Site

Linköping, , Sweden

Site Status

Pfizer Investigational Site

Malmo, , Sweden

Site Status

Pfizer Investigational Site

Mölndal, , Sweden

Site Status

Pfizer Investigational Site

Stockholm, , Sweden

Site Status

Pfizer Investigational Site

Uddevalla, , Sweden

Site Status

Pfizer Investigational Site

Bradford, England, United Kingdom

Site Status

Pfizer Investigational Site

Stirling, Stirlingshire, United Kingdom

Site Status

Pfizer Investigational Site

Swindon, Wiltshire, United Kingdom

Site Status

Pfizer Investigational Site

Bath, , United Kingdom

Site Status

Pfizer Investigational Site

Belfast, , United Kingdom

Site Status

Pfizer Investigational Site

Glasgow, , United Kingdom

Site Status

Pfizer Investigational Site

Glasgow, , United Kingdom

Site Status

Pfizer Investigational Site

Penarth, , United Kingdom

Site Status

Pfizer Investigational Site

Southhampton, , United Kingdom

Site Status

Pfizer Investigational Site

Stirling, , United Kingdom

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States Australia Austria Canada Denmark Germany South Africa Spain Sweden United Kingdom

Related Links

Access external resources that provide additional context or updates about the study.

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

A2581078

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.